The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05426018
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
- Registry
-
NCT05426018
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05426018. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-01 (anticipated); primary completion 2023-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- SY-009 capsules
- Lead sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Record details
- Record id
cardio:ct-nct05426018- Content hash
8b36e5c5aa2983de5f2a9f277bb6b251fdb0a06af10b03207ad10e22c3cfec00